# Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

> **NCT00912938** · PHASE4 · UNKNOWN · sponsor: **Korean Breast Cancer Study Group** · enrollment: 237 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00912938
- **Lead sponsor:** Korean Breast Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 237 (ESTIMATED)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912938, "Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00912938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*